We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

N-acetylcysteine and NMDA Antagonist Interactions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00611897
Recruitment Status : Completed
First Posted : February 11, 2008
Results First Posted : May 8, 2015
Last Update Posted : May 8, 2015
Sponsor:
Information provided by (Responsible Party):

January 29, 2008
February 11, 2008
January 10, 2013
May 8, 2015
May 8, 2015
January 2006
February 2011   (Final data collection date for primary outcome measure)
  • Target P300 [ Time Frame: daily ]

    The Target P300 measures were obtained from the Fz, Cz and Pz electrodes.

    Target stimuli were 1000 Hz tones (500 ms) and novel stimuli (~250 ms) were unique environmental sounds (e.g., dog bark) used in prior studies of the novelty P300. Subjects were instructed to respond to the target sounds by pressing a button using their dominant hand index finger. The standard stimuli were 20, 30 or 40 Hz click trains (500 ms) in the first, second, and third runs, respectively. The auditory steady state EEG driving data obtained from these standard stimuli will be presented in a separate report. All stimuli were presented at 80 dB SPL.

  • Novel P300 [ Time Frame: daily ]

    The Novel P300 measures were obtained from the Fz, Cz and Pz electrodes.

    Target stimuli were 1000 Hz tones (500 ms) and novel stimuli (~250 ms) were unique environmental sounds (e.g., dog bark) used in prior studies of the novelty P300. Subjects were instructed to respond to the target sounds by pressing a button using their dominant hand index finger. The standard stimuli were 20, 30 or 40 Hz click trains (500 ms) in the first, second, and third runs, respectively. The auditory steady state EEG driving data obtained from these standard stimuli will be presented in a separate report. All stimuli were presented at 80 dB SPL.

P300 as detected by ERP [ Time Frame: prospective ]
Complete list of historical versions of study NCT00611897 on ClinicalTrials.gov Archive Site
  • Mismatch Negativity (MMN) Intensity [ Time Frame: daily ]

    Mismatch Negativity (MMN) Intensity difference waves at midline electrodes (Fz, Cz and Pz).

    The frequent standard tones were of 75 ms duration with 5 ms rise and fall time, and were composed of 500, 1000, and 1500 Hz sinusoidal partials (harmonics) that resulted in a single high pitched beep sound.

    All tones were presented at 76 dB sound pressure level (SPL) with the exception of intensity deviants. The three deviants were distinguishable from standard tones in either intensity, frequency, or duration.

    Subjects performed a visual discrimination distractor task during the MMN runs and were instructed to ignore the tones.

    The mismatch negativity (MMN) measure included 3 types of deviant tones (stimuli) that the subjects heard: 1. Frequency deviant, 2. Intensity deviant, 3. Duration deviant. The response to these 3 types of deviants were recorded in the EEG. Therefore each deviant was associated with different waves which we measured in amplitude (microvolts)

  • Mismatch Negativity (MMN) Frequency [ Time Frame: daily ]

    Mismatch Negativity (MMN) Frequency difference waves at midline electrodes (Fx, Cz and Pz).

    The frequent standard tones were of 75 ms duration with 5 ms rise and fall time, and were composed of 500, 1000, and 1500 Hz sinusoidal partials (harmonics) that resulted in a single high pitched beep sound.

    All tones were presented at 76 dB sound pressure level (SPL) with the exception of intensity deviants. The three deviants were distinguishable from standard tones in either intensity, frequency, or duration.

    Subjects performed a visual discrimination distractor task during the MMN runs and were instructed to ignore the tones.

    The mismatch negativity (MMN) measure included 3 types of deviant tones (stimuli) that the subjects heard: 1. Frequency deviant, 2. Intensity deviant, 3. Duration deviant. The response to these 3 types of deviants were recorded in the EEG. Therefore each deviant was associated with different waves which we measured in amplitude (microvolts)

  • Mismatch Negativity (MMN) Duration [ Time Frame: daily ]

    Mismatch Negativity (MMN) Duration difference waves at midline electrodes (Fz, Cz and Pz).

    The frequent standard tones were of 75 ms duration with 5 ms rise and fall time, and were composed of 500, 1000, and 1500 Hz sinusoidal partials (harmonics) that resulted in a single high pitched beep sound.

    All tones were presented at 76 dB sound pressure level (SPL) with the exception of intensity deviants. The three deviants were distinguishable from standard tones in either intensity, frequency, or duration.

    Subjects performed a visual discrimination distractor task during the MMN runs and were instructed to ignore the tones.

    The mismatch negativity (MMN) measure included 3 types of deviant tones (stimuli) that the subjects heard: 1. Frequency deviant, 2. Intensity deviant, 3. Duration deviant. The response to these 3 types of deviants were recorded in the EEG. Therefore each deviant was associated with different waves which we measured in amplitude (microvolts)

MMN [ Time Frame: prospective ]
Not Provided
Not Provided
 
N-acetylcysteine and NMDA Antagonist Interactions
N-acetylcysteine and NMDA Antagonist Interactions
This study tests the hypothesis that extrasynaptic mechanisms are critically linked with cognitive effects of NMDA antagonism as evidenced by event-related potentials (ERPs) in healthy humans.
Not Provided
Interventional
Phase 1
Phase 2
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Cognitive Dysfunction
  • Drug: N-acetylcysteine and ketamine
    Active drug (N-acetylcysteine)
    Other Name: NAC
  • Drug: placebo and ketamine
    placebo N-acetylcysteine
  • Active Comparator: Arm I
    The NAC capsules were administered orally in divided doses: 2000 mg followed by 1000 mg 2 hours later. Each morning, 165 min after NAC administration, subjects received a 1-min bolus of normal saline, followed by a 70-minlong saline infusion during which behavioral, cognitive, and ERP data were collected. Ketamine was administered intravenously as a bolus of .23 mg/kg over 1 min followed by .58 mg/kg for 30 min (SPM and RVP), and then .29 mg/kg for 40 min (P300 and MMN).
    Intervention: Drug: N-acetylcysteine and ketamine
  • Placebo Comparator: Arm II
    The placebo capsules were administered orally in divided doses: 2000 mg followed by 1000 mg 2 hours later. Each morning, 165 min after placebo administration, subjects received a 1-min bolus of normal saline, followed by a 70-minlong saline infusion during which behavioral, cognitive, and ERP data were collected. Ketamine was administered intravenously as a bolus of .23 mg/kg over 1 min followed by .58 mg/kg for 30 min (SPM and RVP), and then .29 mg/kg for 40 min (P300 and MMN).
    Intervention: Drug: placebo and ketamine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
16
February 2011
February 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Ages of 21-45 years from all ethnic backgrounds.
  • Male or female.
  • Written informed consent.

Exclusion criteria

  • DSM-IV diagnosis for a psychotic, depressive or anxiety disorder.
  • A history of significant medical/neurological disease such as cardiac, thyroid, renal, hepatic abnormality, seizure disorder. Unstable medical condition based on EKG, vital signs, physical examination and laboratory work-up (CBC with differential, SMA-7, LFTs, TFTs, UA, Utox, Urine pregnancy test) .
  • History of severe allergies or multiple adverse drug reactions.
  • Any medication that in the opinion of the PI could interfere with either the safety of the study and/or the outcome measures.
  • Any other conditions which in the opinion of the investigator would preclude participation in the study.
  • History of major psychiatric disorder in first degree relatives.
  • Current substance abuse/dependency determined by urine toxicology.
  • Current treatment with medications with psychotropic effects.
  • Treatment with benzodiazepines within one week prior to testing.
  • Current pregnancy, unsatisfactory birth control method report for females.
  • Education < 10th grade.
  • IQ < 70, MR as determined by Wechsler Abbreviated Scale of Intelligence.
  • Non-English speaking.
Sexes Eligible for Study: All
21 Years to 45 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00611897
0508000518
No
Not Provided
Not Provided
Yale University
Yale University
Not Provided
Principal Investigator: Handan Gunduz-Bruce, M.D. Yale School of Medicine
Yale University
May 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP